AIT Therapeutics, Inc. (OTCMKTS:AITB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

AIT Therapeutics, Inc. (OTCMKTS:AITB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 25, 2017, Dr. Jerome B. Zeldis, a director of AIT Therapeutics, Inc., a Delaware corporation (the “Company”), resigned from the Board of Directors with immediate effect. Dr. Zeldis resigned due to the time commitments required for his service on the boards of other public companies and not due to any disagreement with the Company. Dr. Zeldis will remain a member of the Company’s scientific advisory board.

About AIT Therapeutics, Inc. (OTCMKTS:AITB)

AIT Therapeutics, Inc., formerly KokiCare, Inc., is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations. The Company seeks to develop health care enterprise software to be sold to hospitals, medical centers and health care facilities in the United States and internationally. As of September 30, 2016, the Company had not generated any revenues.

AIT Therapeutics, Inc. (OTCMKTS:AITB) Recent Trading Information

AIT Therapeutics, Inc. (OTCMKTS:AITB) closed its last trading session 00.00 at 30.00 with shares trading hands.

An ad to help with our costs